| # | Title | Journal | Year | Citations |
|---|
| 1 | Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project | | 2020 | 329 |
| 2 | Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR | Haematologica | 2018 | 225 |
| 3 | Association between Plasma 25-Hydroxyvitamin D and Breast Cancer Risk | Cancer Prevention Research | 2009 | 114 |
| 4 | A Model for Personalized in Vivo Analysis of Human Immune Responsiveness | Science Translational Medicine | 2012 | 108 |
| 5 | Challenges in lung cancer therapy during the COVID-19 pandemic | Lancet Respiratory Medicine,the | 2020 | 88 |
| 6 | Cancers of the Appendix: Review of the Literatures | ISRN Oncology | 2011 | 70 |
| 7 | Comparative Outcomes of Elderly Stage I Lung Cancer Patients Treated with Segmentectomy via Video-Assisted Thoracoscopic Surgery versus Open Resection | Journal of Thoracic Oncology | 2014 | 68 |
| 8 | Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices | JAMA Oncology | 2019 | 67 |
| 9 | Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials | Leukemia | 2020 | 54 |
| 10 | Immunomodulatory Drugs (IMiDs) in Multiple Myeloma | Current Cancer Drug Targets | 2017 | 50 |
| 11 | Comparative Effectiveness of Robotic-Assisted Surgery for Resectable Lung Cancer in Older Patients | Chest | 2020 | 44 |
| 12 | Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization | Frontiers in Immunology | 2017 | 43 |
| 13 | Biological and Clinical Factors Contributing to the Metabolic Heterogeneity of Hospitalized Patients with and without COVID-19 | Cells | 2021 | 37 |
| 14 | Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk | Journal of Hematology and Oncology | 2020 | 32 |
| 15 | A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors | Investigational New Drugs | 2021 | 28 |
| 16 | A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients | Leukemia and Lymphoma | 2009 | 26 |
| 17 | LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial | Investigational New Drugs | 2021 | 26 |
| 18 | An analysis of the relationship between metastases and cachexia in lung cancer patients | Cancer Medicine | 2016 | 25 |
| 19 | An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes | Cancer Cell | 2022 | 23 |
| 20 | Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors | Seminars in Oncology | 2017 | 22 |
| 21 | Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab | Clinical Cancer Research | 2022 | 21 |
| 22 | Effect of Recombinant Fibroblast Interferon and Recombinant Immune Interferon on Growth and the Antigenic Phenotype of Multidrug-Resistant Human Glioblastoma Multiforme Cells | Journal of the National Cancer Institute | 1991 | 18 |
| 23 | Breast Cancer Prognostic Biomarker Using Attractor Metagenes and the FGD3–SUSD3 Metagene | Cancer Epidemiology Biomarkers and Prevention | 2014 | 18 |
| 24 | Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis | Blood | 2015 | 18 |
| 25 | Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status. | Journal of Clinical Oncology | 2017 | 18 |
| 26 | Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). | Journal of Clinical Oncology | 2020 | 15 |
| 27 | Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions | American Journal of Perinatology | 2018 | 14 |
| 28 | Targeting transcription factors in multiple myeloma: evolving therapeutic strategies | Expert Opinion on Investigational Drugs | 2019 | 13 |
| 29 | A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101 | Oral Oncology | 2021 | 13 |
| 30 | Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers | Cancers | 2021 | 13 |
| 31 | Breast Cancer Risk Assessment and Chemoprevention Use Among Veterans Affairs Primary Care Providers: A National Online Survey | Military Medicine | 2020 | 10 |
| 32 | Targeting cannabinoid receptor‐2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption | Molecular Carcinogenesis | 2015 | 9 |
| 33 | Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma | Blood | 2020 | 9 |
| 34 | Interactions of The Acidic Domain and SRF Interacting Motifs with the NKX3.1 Homeodomain | Biochemistry | 2009 | 6 |
| 35 | Adjuvant Treatment for Elderly Patients with Early-Stage Lung Cancer Treated with Limited Resection | Annals of the American Thoracic Society | 2013 | 6 |
| 36 | Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma | Oncotarget | 2021 | 6 |
| 37 | Efficacy and Safety Results of the Afatinib Expanded Access Program | Oncology and Therapy | 2017 | 5 |
| 38 | Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor | Blood | 2016 | 5 |
| 39 | Induction of growth suppression and modification of gene expression in multi-drug-resistant human glioblastoma multiforme cells by recombinant human fibroblast and immune interferon | International Journal of Cancer | 1992 | 4 |
| 40 | DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR) | Hematological Oncology | 2017 | 4 |
| 41 | Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN) | JCO Oncology Practice | 2021 | 4 |
| 42 | Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors | Molecular Cancer Therapeutics | 2021 | 4 |
| 43 | Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma | Blood | 2020 | 4 |
| 44 | Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR). | Journal of Clinical Oncology | 2017 | 4 |
| 45 | Multiple Myeloma: Defining the High-Risk Patient and Determining the Optimal Treatment Strategy | Current Hematologic Malignancy Reports | 2013 | 3 |
| 46 | Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide | Leukemia and Lymphoma | 2013 | 3 |
| 47 | Therapeutic Options for Aggressive T-Cell Lymphomas | Current Hematologic Malignancy Reports | 2017 | 3 |
| 48 | Pathologic and Clinical Features Of CD30+ Post-Transplant Lymphoproliferative Disorders: A Large Retrospective Single Institutional Study | Blood | 2013 | 3 |
| 49 | Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials | British Journal of Cancer | 2018 | 2 |
| 50 | Neuronal Protection for Chemotherapy Neuropathy Prevention? | Journal of the National Cancer Institute | 2020 | 2 |
